Screening for prostate cancer: Controversy? What controversy?

Current Oncology

Volumn 16, Issue 3, 2009, Pages 1-2

  Ablin, Richard J ^a   Haythorn, M R ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Robert Benjamin Ablin Foundation for Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; EDITORIAL; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MALE; OVARY CANCER; PROSTATE BIOPSY; PROSTATE CANCER; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 70350596110     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v16i3.459     Document Type: Editorial

References (12)

1. Feightner JW on behalf of the Canadian Task Force on Preventive Health Care (CTFPHC). Home 〉 Topics & Recommendations 〉 Neoplasms 〉 4. Screening for Prostate Cancer 〉 Structured Abstract 〉 Printable Version [Web page]. London, ON: CTFPHC; 1998. [Available at: www.ctfphc.org/Abstracts-printable/Ch67abs.htm; cited April 22, 2009]
2. Beaulac JA, Fry RN, Onysko J. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006;97:171-176 (Pubitemid 44043622)
3. Andriole GL, Grubb RL 3rd, Buys SS, et al. on behalf of the PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Eng J Med 2009;360:1310-19. [Erratum in: N Engl J Med 2009;360:1797]
4. Schröder FH, Hugosson J, Roobol MJ, et al. on behalf of the ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Eng J Med 2009;360:1320-1328
5. Ablin RJ, Soanes WA, Bronson P, Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertil 1970;22:573-574
6. Ablin RJ, Bronson P, Soanes WA, Witebsky E. Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 1970;104:1329-1339
7. Ablin RJ. Immunologic studies of normal, benign and malignant human prostatic tissue. Cancer 1972;29:1570-1574
8. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97:1132-1137 (Pubitemid 41511212)
9. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138-144 (Pubitemid 26285528)
10. De Koning HJ, Blom J, Merkelbach JW, et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 2003;92(suppl 2):71-78 (Pubitemid 38091145)
11. United States, Department of Health and Human Services, U.S. Food and Drug Administration (FDA). FDA Approves Test for Prostate Cancer [press release]. Silver Spring, MD: FDA; 1994. [Available online at: www.fda.gov/bbs/topics/ANSWERS/ ANS00598.html; cited April 22, 2009]
12. Bankhead C. MedPage Today (Home) 〉 News By Specialty 〉 Urology 〉 Prostate Cancer 〉 AUA Reaffirms Support for PSA Testing [Web article]. Little Falls, NJ: MedPage Today; 2009. [Available at: www.medpagetoday.com/Urology/Prostate Cancer/13450; cited April 1, 2009]